B. Riley FBR analyst Madhu Kumar upgraded Arrowhead Pharmaceuticals to Buy from Neutral and raised his price target for the shares to $19 from $18. While the data presented this morning are early, they provide clinical proof of concept for Arrowhead's current hepatitis B virus franchise, Kumar tells investors in a research note.

Athira Pharma (ATHA) announced the appointment of Javier San Martin, M.D., as Chief Medical Officer. Dr. San Martin brings more than 25 years of drug development experience and a proven track record leading cross-functional product teams to drive global development and commercialization strategies for multiple drugs across large and rare diseases with significant unmet medical need. San Martin joins Athira from Arrowhead Pharmaceuticals (ARWR), where he served as Chief Medical Officer and guided development teams to advance that company's RNAi-based therapeutics in the metabolic and liver disease area